Simple Summary Solitary fibrous tumor (SFT) is a malignant condition that exhibits different
clinical behaviors ranging from low to high aggressive SFT, with dedifferentiated SFT (DD …

Anti-PD-(L) 1 therapies yield a disappointing response rate of 15% across soft-tissue
sarcomas, even if some subtypes benefit more than others. The proportions of TAMs and …

Highlights•This Clinical Practice Guideline provides key recommendations on the
management of soft tissue and visceral sarcomas.•Recommendations have been agreed …

Simple Summary In the latest WHO classification, solitary fibrous tumors (SFTs) are now
subdivided into benign SFT (intermediate category (locally aggressive)), SFT NOS …

Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment
of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small …

Background Solitary fibrous tumour is an ultra-rare sarcoma, which encompasses different
clinicopathological subgroups. The dedifferentiated subgroup shows an aggressive course …

Solitary fibrous tumour (SFT) is a mesenchymal neoplasm characterised by pathognomonic
NAB2-STAT6 gene fusions. The clinical implications and prognostic value of different fusion …

Surg Oncol Clin N Am 31 (2022) 459–483 https://doi. org/10.1016/j. soc. 2022.03. 009
surgonc. theclinics. com 1055-3207/22/© 2022 Elsevier Inc. All rights reserved …

Solitary fibrous tumors (SFTs) are rare mesenchymal tumors with unpredictable evolution
and with a recurrence or metastasis rate of 10-40%. Current medical treatments for relapsed …

Background Extraskeletal myxoid chondrosarcoma is a rare sarcoma with low sensitivity to
cytotoxic chemotherapy. Retrospective evidence suggests that antiangiogenic drugs could …